# Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

> **NCT05877508** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Michael Peluso, MD** · enrollment: 36 (actual)

## Conditions studied

- Long COVID
- Post-Acute Sequela of COVID-19
- Post-Acute COVID-19

## Interventions

- **DRUG:** AER002
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05877508
- **Lead sponsor:** Michael Peluso, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2024-07-29
- **Final completion:** 2026-07-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-10-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05877508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05877508, "Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05877508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*